| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Q32 Bio Inc. | CEO, Director | Stock Option (Right to Buy) | 394K | $5.29M | $13.42 | Feb 24, 2025 | Direct |
| Q32 Bio Inc. | CEO, Director | Common Stock | 132K | $962K | $7.29 | Feb 24, 2025 | Direct |
| Verve Therapeutics, Inc. | Director | Stock Option (right to buy) | 268K | Jun 26, 2024 | Direct | ||
| AILERON THERAPEUTICS INC | Director | Stock Option (right to buy) | 54.5K | Jun 15, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| QTTB | Q32 Bio Inc. | Feb 24, 2025 | 9 | $0 | 4 | Feb 26, 2025 | CEO, Director |
| VERV | Verve Therapeutics, Inc. | Jun 26, 2024 | 1 | $0 | 4 | Jun 28, 2024 | Director |
| VERV | Verve Therapeutics, Inc. | Jun 26, 2024 | 0 | $0 | 3 | Jun 28, 2024 | Director |
| QTTB | Homology Medicines, Inc. | Mar 25, 2024 | 1 | $0 | 4 | Mar 27, 2024 | CEO, Director |
| QTTB | Homology Medicines, Inc. | Mar 25, 2024 | 0 | $0 | 3 | Mar 27, 2024 | CEO, Director |
| ALRN | AILERON THERAPEUTICS INC | Jun 15, 2022 | 1 | $0 | 4 | Jun 17, 2022 | Director |
| ALRN | AILERON THERAPEUTICS INC | Jun 15, 2021 | 1 | $0 | 4 | Jun 17, 2021 | Director |